CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment

CXC chemokine receptor type 4 (CXCR4) is a member of the G protein-coupled receptors (GPCRs) superfamily and is specific for CXC chemokine ligand 12 (CXCL12, also known as SDF-1), which makes CXCL12/CXCR4 axis. CXCR4 interacts with its ligand, triggering downstream signaling pathways that influence...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2023-08, Vol.149 (10), p.7945-7968
Main Authors: Bao, Shunshun, Darvishi, Mohammad, H Amin, Ali, Al-Haideri, Maysoon T., Patra, Indrajit, Kashikova, Khadisha, Ahmad, Irfan, Alsaikhan, Fahad, Al-qaim, Zahraa Haleem, Al-Gazally, Moaed E., Kiasari, Bahman Abedi, Tavakoli-Far, Bahareh, Sidikov, Akmal A., Mustafa, Yasser Fakri, Akhavan-Sigari, Reza
Format: Article
Language:English
Subjects:
Angiogenesis
Antitumor agents
Apoptosis
Bone marrow
Cancer Research
Cancer therapies
Carcinogenesis
Cell growth
Cell proliferation
Chemokine CXCL12 - genetics
Chemokine receptors
Chemokines
Chemotaxis
CXC chemokines
CXCL12 protein
CXCR4 protein
G protein-coupled receptors
Gene expression
Hematology
Hemopoiesis
HIV
Human immunodeficiency virus
Humans
Hypertension
Immune system
Internal Medicine
Kinases
Leukemia
Leukocyte migration
Ligands
Liver cancer
Lung cancer
Medical research
Medicine
Medicine & Public Health
Metastases
Metastasis
Multiple myeloma
Neoplasms - genetics
Oncology
Organogenesis
Pharmacy
Physiology
Prostate
Proteins
Pulmonary arteries
Receptors, CXCR4 - genetics
Review
SDF-1 protein
Signal Transduction
Stem cells
Tumors
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CXC chemokine receptor type 4 (CXCR4) is a member of the G protein-coupled receptors (GPCRs) superfamily and is specific for CXC chemokine ligand 12 (CXCL12, also known as SDF-1), which makes CXCL12/CXCR4 axis. CXCR4 interacts with its ligand, triggering downstream signaling pathways that influence cell proliferation chemotaxis, migration, and gene expression. The interaction also regulates physiological processes, including hematopoiesis, organogenesis, and tissue repair. Multiple evidence revealed that CXCL12/CXCR4 axis is implicated in several pathways involved in carcinogenesis and plays a key role in tumor growth, survival, angiogenesis, metastasis, and therapeutic resistance. Several CXCR4-targeting compounds have been discovered and used for preclinical and clinical cancer therapy, most of which have shown promising anti-tumor activity. In this review, we summarized the physiological signaling of the CXCL12/CXCR4 axis and described the role of this axis in tumor progression, and focused on the potential therapeutic options and strategies to block CXCR4.
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-022-04444-w